• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[药物性鼻炎的研究进展]

[Research progress on rhinitis medicamentosa].

作者信息

Wang Y N, Luan Z L, Wang H T

机构信息

Department of Otorhinolaryngology Head and Neck Surgery, Chinese PLA General Hospital, Beijing 100853, China.

出版信息

Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Nov 7;52(11):872-875. doi: 10.3760/cma.j.issn.1673-0860.2017.11.019.

DOI:10.3760/cma.j.issn.1673-0860.2017.11.019
PMID:29141305
Abstract

Rhinitis medicamentosa (RM) refers to nonallergic inflammation in the nasal mucosa which is caused by the abuse of nasal decongestant and it often occurs in patients with allergic/nonallergic rhinitis along with nasal congestion. RM is characterized by nasal congestion based on long-term use of nasal decongestant, without rhinorrhoea or sneezing. The signs of RM include nasal swelling, thickening, loss of elasticity, and loss of sensitivity to the decongestant. The histological changes of RM are loss of nasal mucosa cilia, squamous epithelium metaplasia, edema of epithelium cell, hyperplasia of goblet cell, increased expression of epidermal growth factor receptor and infiltration of inflammatory cells, etc. There is no precise diagnosis standard for RM, making it even harder for its objective diagnosis. Patients with RM should immediately stop using nasal decongestant, in stead of using nasal glucocorticoid spray for the recovery of the nasal mucosa's function.

摘要

药物性鼻炎(RM)是指因滥用鼻减充血剂引起的鼻黏膜非过敏性炎症,常发生于过敏性/非过敏性鼻炎伴鼻充血患者中。药物性鼻炎的特征是基于长期使用鼻减充血剂而出现鼻充血,无流涕或打喷嚏症状。药物性鼻炎的体征包括鼻肿胀、增厚、弹性丧失以及对减充血剂敏感性丧失。药物性鼻炎的组织学变化为鼻黏膜纤毛丧失、鳞状上皮化生、上皮细胞水肿、杯状细胞增生、表皮生长因子受体表达增加以及炎性细胞浸润等。目前尚无药物性鼻炎的确切诊断标准,这使得其客观诊断更加困难。药物性鼻炎患者应立即停用鼻减充血剂,而应使用鼻用糖皮质激素喷雾剂来恢复鼻黏膜功能。

相似文献

1
[Research progress on rhinitis medicamentosa].[药物性鼻炎的研究进展]
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Nov 7;52(11):872-875. doi: 10.3760/cma.j.issn.1673-0860.2017.11.019.
2
Rhinitis medicamentosa.药物性鼻炎
J Investig Allergol Clin Immunol. 2006;16(3):148-55.
3
Mucosal changes in rhinitis medicamentosa.药物性鼻炎的黏膜变化
Ann Otol Rhinol Laryngol. 2004 Feb;113(2):147-51. doi: 10.1177/000348940411300213.
4
[Rhinitis medicamentosa in cytological assessment of the nasal mucosa].[药物性鼻炎在鼻黏膜细胞学评估中的情况]
Pol Merkur Lekarski. 2005 Sep;19(111):288-90.
5
[Ultrastructural changes in human nasal mucosa in rhinitis medicamentosa].[药物性鼻炎患者鼻黏膜的超微结构变化]
HNO. 2006 Oct;54(10):742-8. doi: 10.1007/s00106-005-1370-7.
6
Rhinitis medicamentosa. An experimental histopathological and histochemical study.药物性鼻炎。一项实验性组织病理学和组织化学研究。
ORL J Otorhinolaryngol Relat Spec. 1983;45(4):187-94. doi: 10.1159/000275642.
7
Topical hyaluronic acid in rhinitis medicamentosa: could our perspective be changed?变应性鼻炎药物相关性鼻炎中局部用透明质酸:我们的观点能否改变?
J Biol Regul Homeost Agents. 2017 Dec 27;31(4 Suppl 2):55-62.
8
One-week use of oxymetazoline nasal spray in patients with rhinitis medicamentosa 1 year after treatment.药物性鼻炎患者治疗1年后使用羟甲唑啉鼻喷雾剂1周。
ORL J Otorhinolaryngol Relat Spec. 1997 Jan-Feb;59(1):39-44. doi: 10.1159/000276903.
9
Rebound congestion and rhinitis medicamentosa: nasal decongestants in clinical practice. Critical review of the literature by a medical panel.反弹性充血和药物性鼻炎:临床实践中的鼻腔减充血剂。医学专家组对文献的批判性回顾。
Eur Ann Otorhinolaryngol Head Neck Dis. 2013 Jun;130(3):137-44. doi: 10.1016/j.anorl.2012.09.005. Epub 2013 Feb 1.
10
Adverse effects of benzalkonium chloride on the nasal mucosa: allergic rhinitis and rhinitis medicamentosa.苯扎氯铵对鼻黏膜的不良反应:过敏性鼻炎和药物性鼻炎。
Clin Ther. 1999 Oct;21(10):1749-55. doi: 10.1016/S0149-2918(99)80053-8.

引用本文的文献

1
Effects of liposomal nasal spray with vitamins A and E on allergic rhinitis.含维生素A和E的脂质体鼻喷雾剂对变应性鼻炎的影响。
Acta Otorhinolaryngol Ital. 2020 Jun;40(3):217-223. doi: 10.14639/0392-100X-N0357.